CJC-1295 with DAC
≥99% HPLC verified · 1 size available
Synthetic GHRH analog with drug affinity complex modification, studied in endocrine pathway research.
What research has shown
Synthetic compound
Defined synthetic material for controlled laboratory research and analytical method development.
In the literature
Cited across published research on peptide stability, receptor interaction, and biological signaling.
Lab settings
Examined in vitro and in preclinical models. Studies focus on molecular properties under controlled systems.
Non-therapeutic
For laboratory research only. Not approved for human consumption, treatment, or therapeutic application.
About this compound
CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with a drug affinity complex (DAC) covalently linking the peptide to serum albumin upon administration. The DAC modification extends plasma half-life relative to native GHRH or unmodified CJC-1295. The compound is referenced in research literature on long-acting GHRH-receptor pathway signaling and pulsatile-release research models.
Each Perplexa lot is independently HPLC-verified at ≥99% purity with identity confirmed by mass spectrometry.
This material is supplied for in vitro research only. It is not a drug, supplement, food, or cosmetic, and is not for human or veterinary consumption.
This material is supplied for in vitro research only. It is not a drug, supplement, food, or cosmetic, and is not for human or veterinary consumption.
Specifications
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC) |
| Size | 5MG |
| Vial | 3ML |
| Storage | -20°C, desiccated, protected from light |
| Origin | USA |
| Mol. Weight | 3367.85 g/mol |
| Identity | Mass spectrometry |
Reconstitution, storage, and handling are the responsibility of the qualified researcher.Perplexa Labs does not provide protocols, dosing guidance, or human-use instructions.